Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Acrivon Therapeutics, Inc

< Previous 1 2 Next >
News headline image
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development Candidate, ACR-2316
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Participate in a Panel Discussion at the TD Cowen 44th Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Highlight its ACR-368 OncoSignature Test, Used in Ongoing Phase 2 Study to Treat Patients Based on Predicted Sensitivity to Monotherapy with its CHK1/2 Inhibitor ACR-368, at the Upcoming AACR-NCI-EORTC International Conference on
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Participate in Two Investor Conferences in September
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Present at the Jefferies Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Host Virtual Investor Event on May 1, 2023
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Present at the Stifel 2023 Targeted Oncology Days Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
News headline image
Acrivon Therapeutics to Participate on a Panel at Cowen’s 43rd Annual Health Care Conference
From Acrivon Therapeutics, Inc
Via GlobeNewswire
Tickers ACRV
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback